TY  - JOUR
AU  - Blobner, Jens
AU  - Ruf, Viktoria
AU  - Weller, Jonathan
AU  - Teske, Nico
AU  - Forbrig, Robert
AU  - Thon, Niklas
AU  - Albert, Nathalie L
AU  - von Baumgarten, Louisa
AU  - Schoenecker, Stephan
AU  - Tonn, Joerg-Christian
AU  - Ringel, Florian
AU  - Harter, Patrick
AU  - Karschnia, Philipp
TI  - Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.
JO  - Journal of neuro-oncology
VL  - 175
IS  - 2
SN  - 0167-594X
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - DKFZ-2025-01505
SP  - 763-774
PY  - 2025
N1  - 2025 Nov;175(2):763-774
AB  - The 2021 WHO classification of CNS tumors allows flexibility in the grading of IDH-mutant astrocytic gliomas, leading to some ambiguity. Following the approval of vorasidenib for WHO grade 2 astrocytomas and oligodendrogliomas based on the positive Phase III INDIGO trial, identifying prognostic criteria to differentiate between grade 2 and grade 3 tumors has become increasingly important.We retrospectively searched our institutional database for patients meeting the diagnostic criteria for IDH-mutant astrocytomas (grade 2 and 3) according to the WHO 2021 classification. Clinical, radiological and molecular data were collected; outcome was compared using log-rank analysis and prognostic markers were subsequently forwarded in a multivariate model.We identified 91 patients with IDH-mutant astrocytomas with available neuropathological and clinical data, including 61 WHO grade 2 (67.0
KW  - Astrocytoma (Other)
KW  - Contrast-enhancement (Other)
KW  - Grading (Other)
KW  - IDH-inhibitor (Other)
KW  - IDH-mutant (Other)
KW  - Mitotic count (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40702387
DO  - DOI:10.1007/s11060-025-05173-z
UR  - https://inrepo02.dkfz.de/record/303080
ER  -